linkedin

IR Notice

Notice

CEO IR Newsletter



 

Dear Investors, This is John Rim, CEO of Samsung Biologics. We sincerely appreciate your continued trust and support this year. 2021, our 10th year since the foundation of Samsung Biologics, has come to an end. Despite continued worldwide uncertainties, now greater than ever due to the prolonged COVID-19 pandemic, our three plants all maintained stable utilization thanks to our strong backlog and operational excellence. In addition, we are proud to highlight the following significant achievements:

COVID-19 Vaccine/Drug CMO
Moderna Vaccine DP Manufacturing Contract GSK/VIR, Lilly, AZ Antibody MFG Contracts
Multi Modal Plant Expansion
Songdo Section 5 (10,279m²) Land Acquisition
mRNA DS Expansion
May 21 Announced 1 Half 22 GMP-Ready Partnership with "Greenlight Biosciences
S-CellerateTM Launch
Accelerated platform for cell line development

We have also bolstered our efforts on ESG (Environmental, Social and Governance) management and accomplished the following:

  • 5 Global ISO Certifications ISO 22301, ISO 45001, ISO 14001, ISO 50001, ISO 9001
  • First Sustainability Report Issued
  • Frontier-1.5D Participation
  • ESG Rating 'A Grade' from KCGS
  • Dow Jones Sustainability World Index Inclusion
  • SMI Health Systems Supply Chains Working Group Champion *Sustainable Market Initiative

As everyone struggled together to return to normal, Samsung Biologics was proud to serve our part by not only providing high quality, end-to-end CDMO services crucial to our global clients, but also as a responsible member of society for greater sustainability. In 2022, we will continue to put forth our best efforts to pursue a better life for humanity in addition to our continuous growth. In our journey to a brighter future, we will continue to actively communicate with investors to update on our progress and results. This winter feels colder than ever with the pandemic, and we wish you an abundance of joy, health, and a happy year-end and New Year's holidays.

Thank you. Sincerely, John Rim President and CEO, Samsung Biologics




 

Dear Investors, This is John Rim, CEO of Samsung Biologics. We sincerely appreciate your continued trust and support this year. 2021, our 10th year since the foundation of Samsung Biologics, has come to an end. Despite continued worldwide uncertainties, now greater than ever due to the prolonged COVID-19 pandemic, our three plants all maintained stable utilization thanks to our strong backlog and operational excellence. In addition, we are proud to highlight the following significant achievements:

COVID-19 Vaccine/Drug CMO
Moderna Vaccine DP Manufacturing Contract GSK/VIR, Lilly, AZ Antibody MFG Contracts
Multi Modal Plant Expansion
Songdo Section 5 (10,279m²) Land Acquisition
mRNA DS Expansion
May 21 Announced 1 Half 22 GMP-Ready Partnership with "Greenlight Biosciences
S-CellerateTM Launch
Accelerated platform for cell line development

We have also bolstered our efforts on ESG (Environmental, Social and Governance) management and accomplished the following:

  • 5 Global ISO Certifications ISO 22301, ISO 45001, ISO 14001, ISO 50001, ISO 9001
  • First Sustainability Report Issued
  • Frontier-1.5D Participation
  • ESG Rating 'A Grade' from KCGS
  • Dow Jones Sustainability World Index Inclusion
  • SMI Health Systems Supply Chains Working Group Champion *Sustainable Market Initiative

As everyone struggled together to return to normal, Samsung Biologics was proud to serve our part by not only providing high quality, end-to-end CDMO services crucial to our global clients, but also as a responsible member of society for greater sustainability. In 2022, we will continue to put forth our best efforts to pursue a better life for humanity in addition to our continuous growth. In our journey to a brighter future, we will continue to actively communicate with investors to update on our progress and results. This winter feels colder than ever with the pandemic, and we wish you an abundance of joy, health, and a happy year-end and New Year's holidays.

Thank you. Sincerely, John Rim President and CEO, Samsung Biologics

SITE MAP

close
Close

Your download is ready

Click Download.

Close

Subscribe to Our Newsletter

Subscribe to our newsletter to download.
*If you have already subscribed, enter your email.

뉴스레터 구독 서비스 유무 확인
Close

Subscribe to Our Newsletter

Please fill in your details, select one or more areas of interest, and click the subscribe button to receive our newsletter.

Subscribe to Our Newsletter
  • Privacy Policy to collect the email address that I have provided until I withdraw my consent. The collected information will only be used for the purpose of mailing service. If you do not wish to consent, you will not be able to receive the newsletter. Samsung Biologics respects the privacy of its subscribers.
close

SECURITY REPORT

Your valuable comments contribute to protecting Samsung Biologic’s core technology and management information, as well as reinforcing domestic competency and economic development.

  • This page is created for reporting core technology and management information leakage.
  • The reported contents as well as the identity of the reporter are strictly secured.
THE MANUAL FOR SECURITY NOTIFICATION

Copyright Samsung Biologics. All rights reserved